When Cancer and Its Treatments Trigger Diabetes, and Why Doctors Should Look Both Ways
A Lancet Diabetes Endocrinology review explores how cancer drugs and tumours themselves can cause dysglycaemia, sometimes appearing as diabetes first.
Riepilogo
Cancer and diabetes influence each other in both directions. This narrative review looks at how cancer and its treatments can cause high blood sugar, a form of secondary diabetes. It covers PI3K-AKT-mTOR inhibitors, antibody-drug conjugates, immune checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands used in neuroendocrine tumours, and explains the distinct ways each can disrupt glucose control. The authors also stress that new-onset diabetes can be an early sign of an undiagnosed cancer, which is easily overlooked. Case vignettes illustrate these scenarios. The review identifies research gaps and calls for closer collaboration between endocrinologists and oncologists to manage rising dysglycaemia as cancer therapies evolve. Only the abstract was available, so specific numbers, thresholds, and management recommendations could not be assessed.
Riepilogo Dettagliato
Diabetes is usually discussed as type 1 or type 2, but a growing share of cases arise from other causes, including cancer and cancer therapy. As survival improves and new drugs reach the clinic, more patients live with treatment-related blood sugar problems, which can affect treatment tolerance, infection risk, and outcomes.
This Lancet Diabetes & Endocrinology review, written by endocrinologists and an oncologist, has three aims. First, it summarises how dysglycaemia arises from cancer and neuroendocrine tumour treatments, including PI3K-AKT-mTOR inhibitors, antibody-drug conjugates, immune checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands. Second, it examines new diabetes as an early manifestation of cancer. Third, it highlights research gaps and advocates collaborative care.
Based on the abstract, the key message is that these drug classes cause hyperglycaemia through different mechanisms, so management may need to differ by agent. The review also argues that secondary diabetes as a possible early signal of malignancy is underappreciated. Case vignettes are used to ground these points in clinical scenarios.
For practice, the review supports closer collaboration between endocrinology and oncology teams, with attention to glucose monitoring during therapy and to atypical presentations of new diabetes. Clinicians may want to consider an underlying malignancy when diabetes appears unexpectedly.
Caveats: this summary rests solely on the abstract. It is a narrative review rather than a systematic analysis or trial, so the strength of evidence, specific risk estimates, and treatment algorithms cannot be verified here. Several authors report industry relationships, including with manufacturers of diabetes and oncology drugs.
Risultati Principali
- Cancer and diabetes have a bidirectional relationship, with cancer increasingly recognised as a cause of secondary diabetes.
- Dysglycaemia arises through distinct mechanisms across PI3K-AKT-mTOR inhibitors, antibody-drug conjugates, checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands.
- New-onset diabetes can be an overlooked early manifestation of an underlying cancer.
- The review calls for collaborative endocrinology-oncology care as cancer therapies evolve and dysglycaemia rates rise.
- Research gaps in managing treatment-related dysglycaemia are highlighted; case vignettes illustrate clinical scenarios.
Metodologia
This is a narrative review published in Lancet Diabetes & Endocrinology. It synthesises mechanisms of cancer- and treatment-related dysglycaemia and uses case vignettes to illustrate clinical points. The abstract does not describe a systematic search or formal evidence grading.
Limitazioni dello Studio
Only the abstract was available, so details on mechanisms, incidence, and management recommendations could not be evaluated. As a narrative review, it is subject to selection bias and does not provide new primary data. Multiple authors disclose industry ties relevant to diabetes and oncology therapeutics.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: